

was resuspended in 3 times the original volume of buffer and incubated at 37 °C for 15 min, centrifuged again, and resuspended in the original volume of buffer. A binding assay using [<sup>3</sup>H]-bremazocine (0.5 nM) was carried out as described above.

**Acknowledgment.** We greatly appreciate receiving samples of benzomorphan standards 1, its enantiomer, 2, (2*R*)- and (2'*S*)-3, and the enantiomer of (2'*S*)-3 from Dr. Herbert Merz, Boehringer Ingelheim KG, Germany. We acknowledge the support of this work by the National Institute on Drug Abuse through research grants DA-03933 and DA-06675.


## Preparation and Anticonvulsant Activity of a Series of Functionalized $\alpha$ -Heteroatom-Substituted Amino Acids

Harold Kohn,\*<sup>†</sup> Kailash N. Sawhney,<sup>†</sup> Philippe LeGall,<sup>†</sup> David W. Robertson,<sup>†</sup> and J. David Leander<sup>†</sup>

Department of Chemistry, University of Houston, Houston, Texas 77204-5641, and Lilly Research Laboratories, Eli Lilly Company, Indianapolis, Indiana 46285. Received December 4, 1990

Potent anticonvulsant activity has been reported for (*R,S*)-2-acetamido-*N*-benzyl-2-methylacetamide (**2a**). Select  $\alpha$ -heteroatom substituted derivatives of **2a** have been prepared (26 examples) in which the  $\alpha$ -methyl group has been replaced by nitrogen (**3a-q**), oxygen (**3r-u**), and sulfur (**3v-z**) containing moieties. The functionalized amino acid derivatives were evaluated in the maximal electroshock seizure (MES) and horizontal screen (tox) tests in mice. The most active compounds were (*R,S*)-2-acetamido-*N*-benzyl-2-(methoxyamino)acetamide (**3l**), and (*R,S*)-2-acetamido-*N*-benzyl-2-(methoxymethylamino)acetamide (**3n**). After ip administration, the MES ED<sub>50</sub> values for **3l** (6.2 mg/kg) and **3n** (6.7 mg/kg) compared favorably with phenytoin (9.50 mg/kg).

Nonnaturally occurring amino acids have become increasingly important in the design of pharmacologically active peptides and peptidomimetics.<sup>1</sup> Recently we reported the excellent anticonvulsant activity of certain functionalized amino acid derivatives 1.<sup>2-6</sup> Potent protection against maximal electroshock seizures (MES) in mice was observed for functionalized amino acid racemates containing both an *N*-benzylamide moiety and an acetylated amino group. Systematic variation of the  $\alpha$ -substituent revealed that stringent steric and electronic requirements must be met for optimal activity. The median effective dose (ED<sub>50</sub>) for the  $\alpha$ -methyl (**2a**) (76.5 mg/kg) and  $\alpha$ -phenyl (**2b**) (20.3 mg/kg) derivatives<sup>4</sup> compared favorably with that observed for phenobarbital<sup>7</sup> (21.8 mg/kg), while those of the  $\alpha$ -pyrrolyl (**2c**) (16.1 mg/kg) and  $\alpha$ -furanlyl (**2d**) (10.3 mg/kg) adducts<sup>6</sup> rivaled that reported for phenytoin<sup>7</sup> (9.50 mg/kg). Furthermore, comparison of the two individual enantiomers of **2a,b,d** revealed that in each case the anticonvulsant activity resided primarily in the *R* stereoisomer.<sup>2,5,6</sup>



1

2a R<sup>2</sup> = CH<sub>3</sub>b R<sup>2</sup> = Phc R<sup>2</sup> = 2-pyrrolyld R<sup>2</sup> = 2-furanlyl

In the present study, the synthesis and anticonvulsant properties of a novel series of  $\alpha$ -heteroatom-substituted

**Registry No.** 4, 134133-69-0; 5, 134233-45-7; 6, 134233-46-8; 7, 134233-47-9; 8, 134133-70-3; 8-HCl, 134233-67-3; 9, 134233-48-0; 9-HCl, 134308-16-0; ( $\pm$ )-10, 52079-30-8; (5*R*)-11, 58879-35-9; (5*S*)-11, 58879-36-0; 12, 134133-71-4; 13, 134233-49-1; 14, 134133-72-5; 15, 134233-50-4; 16 (isomer 1), 134133-73-6; 16 (isomer 2), 134233-51-5; 18 (isomer 1), 134133-74-7; 18 (isomer 2), 134233-52-6; 20, 134133-75-8; 21, 134233-53-7; 22, 134233-54-8; 23, 134233-55-9; 24, 134233-56-0; 25, 134233-57-1; 30, 134233-58-2; 31, 134233-59-3; 32 (isomer 1), 134133-76-9; 32 (isomer 2), 134233-60-6; 33 (isomer 1), 134133-77-0; 33 (isomer 2), 134233-61-7; 33 (isomer 1)-HCl, 134233-62-8; 33 (isomer 2)-HCl, 134308-15-9; 34 (isomer 1), 134233-63-9; 34 (isomer 2), 134233-64-0; 35 (isomer 1), 134233-65-1; 35 (isomer 2), 134233-66-2.

amino acid derivatives (26 examples) are presented. Included in this survey are selected oxygen, nitrogen, and sulfur-functionalized amino acids. Analysis of the composite data set disclosed trends that further define the structure-activity relationships for this class of amino acid derived anticonvulsant agents.

### Selection of Compounds

(*R,S*)-2-Acetamido-*N*-benzyl-2-methylacetamide<sup>3</sup> (**2a**) represented the parent compound in this study wherein the  $\alpha$ -methyl group was replaced by select functionalized nitrogen, oxygen, and sulfur substituents (Table I). In all cases, the racemates were prepared and tested. No attempts were made at this stage to resolve the enantiomeric mixtures. The  $\alpha$ -nitrogen-substituted adducts consisted of the parent amino **3a**, the monoalkylamino **3b,c**, the dialkylamino **3d,e**, and the trialkylammonium **3f** derivatives, as well as the corresponding monoaryl analogues **3g** and **3h**. Included in our  $\alpha$ -nitrogen subset of compounds were three classes of functionalized amino derivatives. These were the monoacyl derivatives **3i** and **3j**, the *N*-hydroxyamino adducts **3k-o**, and the *N*-hydrazino compounds **3p** and **3q**. The second set of structurally modified amino acid derivatives were the




- (1) For leading references, see: (a) Shuman, R. T.; Ornstein, P. L.; Paschal, J. W.; Gesellchen, P. D. *J. Org. Chem.* **1990**, *55*, 738. (b) Ojima, I.; Komata, T.; Qiu, X. *J. Am. Chem. Soc.* **1990**, *112*, 770 and references therein.
- (2) Kohn, H.; Conley, J. D. *Chem. Br.* **1988**, *24*, 231.
- (3) Cortes, S.; Liao, Z.-K.; Watson, D.; Kohn, H. *J. Med. Chem.* **1985**, *28*, 601.
- (4) Conley, J. D.; Kohn, H. *J. Med. Chem.* **1987**, *30*, 567.
- (5) Kohn, H.; Conley, J. D.; Leander, J. D. *Brain Res.* **1988**, *457*, 371.
- (6) Kohn, H.; Sawhney, K. N.; LeGall, P.; Conley, J. D.; Robertson, D. W.; Leander, J. D. *J. Med. Chem.* **1990**, *33*, 919.
- (7) Porter, R. J.; Cereghino, J. J.; Gladding, G. D.; Hessie, B. J.;

\* Author to whom correspondence should be addressed to at the University of Houston.

<sup>†</sup> University of Houston

Table I. Selected Physical and Pharmacological Data in Mice for  $\alpha$ -Heteroatom-Substituted Functionalized Amino Acid Derivatives 3<sup>a</sup>

$$\begin{array}{c} \text{O} \quad \text{X} \quad \text{O} \\ \parallel \quad | \quad \parallel \\ \text{CH}_3\text{CNH} - \text{CH} - \text{CNHCH}_2\text{Ph} \\ 3 \end{array}$$





no.	X	mp <sup>b</sup>	MES <sup>c</sup> ED <sub>50</sub>	tox <sup>d</sup> TD <sub>50</sub>
3a	NH <sub>2</sub>	131-133	65.1 [0.5] (56.2-75.3)	e
3b	NHCH <sub>3</sub>	115-117	44.5 [0.5] (37.0-52.4)	e
3c	NHCH <sub>2</sub> CH <sub>3</sub>	123-125	42.4 [0.5] (37.2-47.8)	e
3d	N(CH <sub>3</sub> ) <sub>2</sub>	104-106	45.3 [1]	e
3e		171-172	>30, <100 [1]	e
3f	N <sup>+</sup> (CH <sub>3</sub> ) <sub>3</sub> BF <sub>4</sub> <sup>-</sup>	171-173 dec	>100	e
3g	NHPh	183-185	>300	e
3h		135-137	~100 [1]	e
3i	NHCOCH <sub>3</sub>	265-267 dec	>100, <300 [1]	e
3j	NHCOCF <sub>3</sub>	228-230	>300	e
3k	NHOH	144-146 dec	~100 [1]	e
3l	NH(OCH <sub>3</sub> )	95-97	6.2 [0.5] (5.4-7.2)	46.0 [0.5] (38.0-56.0)
3m	N(CH <sub>3</sub> )OH	159-161	~30 [1]	e
3n	N(CH <sub>3</sub> )OCH <sub>3</sub>	165-167	6.7 [0.5] (5.7-7.7)	50.5 [0.5] (40.4-59.9)
3o		149-151	31.4 [0.5] (26.7-37.8)	e
3p	NHNHPh	132-134	~100 [0.5]	e
3q	NHNHCO <sub>2</sub> CH <sub>2</sub> Ph	152-154	55.6 [0.5] (49.3-63.9)	e
3r	OH	136-138	80.1 [1] (70.6-91.0)	e
3s <sup>f</sup>	OCH <sub>3</sub>	145-146	98.3 [0.5] (84.4-114.0)	>100, <300 [0.5]
3t <sup>f</sup>	OCH <sub>2</sub> CH <sub>3</sub>	153-155	62.0 [1] (51.1-78.4)	>112
3u	OPh	125-128	>100 <sup>g</sup>	e
3v	SCH <sub>3</sub>	155-157	>100	e
3w	SCH <sub>2</sub> CH <sub>3</sub>	140-142	>30, <100 [0.5]	e
3x <sup>f</sup>	SPh	165-167	>300	e
3y-1	S(O)CH <sub>2</sub> CH <sub>3</sub>	135-137	>100	e
3y-mix	S(O)CH <sub>2</sub> CH <sub>3</sub>	135-137	>100	e
3z	S(O <sub>2</sub> )CH <sub>2</sub> CH <sub>3</sub>	161-163	>100	e
2a <sup>h</sup>	CH <sub>3</sub>	138-139	76.5 (66.6-89.0)	453.9 <sup>i</sup> (416.6-501.0)
2b <sup>j</sup>	Ph	202-203	20.3 (16.9-24.5)	96.9 <sup>j</sup> (79.8-118.4)
2c <sup>k</sup>	2-pyrrolyl	174-175	16.1 (13.2-19.9)	>30, <100
2d <sup>k</sup>	2-furanyl	178-179	10.3 (9.1-11.6)	~40
phenytoin <sup>l</sup>			9.5 (8.1-10.4)	65.5 <sup>l</sup> (52.5-72.1)
phenobarbital <sup>l</sup>			21.8 (15.0-22.5)	69.0 <sup>l</sup> (62.8-72.9)
valproate <sup>l</sup>			272 (247-338)	426 <sup>l</sup> (369-450)

<sup>a</sup> The compounds were administered intraperitoneally. ED<sub>50</sub> and TD<sub>50</sub> values are in milligrams per kilogram. Number in parentheses are 95% confidence intervals. Time of peak effects in hours as determined in the Experimental Section is denoted in brackets. <sup>b</sup> Melting points (°C) are uncorrected. <sup>c</sup> MES = maximal electroshock seizure test. Compound was suspended in 30% PEG unless otherwise noted. <sup>d</sup> Tox = neurologic toxicity determined from horizontal screen unless otherwise noted. <sup>e</sup> Not determined. <sup>f</sup> Reference 8. <sup>g</sup> Compound 3u was suspended in acacia. <sup>h</sup> Reference 3. <sup>i</sup> Neurologic toxicity determined using the rotorod test. <sup>j</sup> Reference 4. <sup>k</sup> Reference 6. <sup>l</sup> Reference 7.

$\alpha$ -oxygen-substituted compounds 3r-u. This group was comprised of the  $\alpha$ -hydroxy adduct 3r, the two  $\alpha$ -alkoxy derivatives 3s and 3t,<sup>8</sup> and the  $\alpha$ -phenoxy compound 3u.

A similar battery of  $\alpha$ -sulfur-substituted compounds (i.e., 3v-x<sup>8</sup>) was selected for evaluation. Attempts to synthesize the parent  $\alpha$ -thiol derivative in the series were unsuccessful, however. In addition to 3v-x, both the sulfoxide 3y and the sulfone 3z derivatives of the ethylthio adduct


(8) LeGall, P.; Sawhney, K. N.; Conley, J. D.; Kohn, H. *Int. J.*

**Scheme I. Preparation of  $\alpha$ -Heteroatom-Substituted Functionalized Amino Acid Derivatives 3***Method A:**Method B:**Method C:**Method D:***Chemistry**

Four different synthetic approaches (Scheme I, methods A–D) were employed for the preparation of most of the  $\alpha$ -heteroatom-substituted, functionalized amino acid derivatives **3**. In the first route (method A), the  $\alpha$ -bromo ester **5** was prepared in near quantitative yield using the protocol of Kober and Steglich<sup>9</sup> from commercially available<sup>10</sup> ethyl acetamidoacetate (**4**). Treatment of **5** with an excess of the nucleophilic heteroatom species furnished the corresponding ethyl 2-substituted-2-acetamidoacetate **6** (61–92% yields). Formation of **6** is presumed to proceed through the intermediacy of ethyl 2-(acetylimino)acetate. In most cases, **6** was isolated as a thick oil and used directly in the subsequent step without extensive purification. Treatment of **6** with benzylamine and a catalytic amount of NaCN<sup>11</sup> gave the desired product in moderate yields (29–74%). This method was used to synthesize compounds **3a–c**, **3e**, **3g**, and **3h**. Attempts to utilize this protocol to prepare **3d**, **3k**, **3m**, and **3n** were unsatisfactory. In these cases the final benzylamine-mediated step did not proceed cleanly.

The difficulty encountered in converting several  $\alpha$ -functionalized esters **6** to the corresponding benzylamides **3** led to the development of the second procedure (method B) depicted in Scheme I. In this route the benzylamide moiety was incorporated within the framework of the amino acid derivative prior to the introduction of the  $\alpha$ -heteroatom substituent. Treatment of **3t** with BBr<sub>3</sub> in CH<sub>2</sub>Cl<sub>2</sub> led to the formation of the presumed  $\alpha$ -bromo derivative **7**. This adduct could not be fully purified or

characterized due to the sensitivity of **7** to moisture and its poor solubility in nonhydroxylic solvents. Accordingly, either the addition of an excess of the heteroatom species or the sequential addition of triethylamine and the nucleophilic heteroatom-containing reagent to a THF mixture containing **7** furnished **3** in moderate amounts (21–38% yields from **3t**). This method was employed for the preparation of compounds **3d**, **3k**, **3p**, and **3u–w**. Included in the product mixture for **3k** were the diastereomeric adducts **8a** and **8b** in which 2 equiv of **7** reacted with NH<sub>2</sub>OH. Implementation of this procedure for the synthesis of **3l–o** was not successful due to the difficulty encountered in obtaining solutions of the free hydroxyamines in nonhydroxylic solvents. Use of methanolic solutions of the hydroxyamines furnished only **3s**.



Employment of the third protocol (method C) outlined in Scheme I provided a convenient procedure to circumvent this obstacle. Methylation of the dimethylamino adduct **3d** with trimethyloxonium tetrafluoroborate<sup>10</sup> in nitromethane furnished the quaternary ammonium derivative **3f** in high yields. Subsequent treatment of **3f** with a methanolic solution containing the requisite hydroxyamine led to production of **3l–o** in good yields (42–82%).

Synthesis of the  $\alpha$ -hydroxy (**3r**),  $\alpha$ -ethylthio (**3w**), and  $\alpha$ -thiophenoxy<sup>8</sup> (**3x**) amino acid derivatives was accomplished using the last technique depicted in Scheme I in which **3t** was treated with BF<sub>3</sub>·Et<sub>2</sub>O in the presence of H<sub>2</sub>O, EtSH, and PhSH, respectively (Scheme I, method D). A similar protocol was utilized by us for the preparation of  $\alpha$ -heteroaromatic functionalized amino acid derivatives.<sup>6,8</sup> This procedure proved superior than that of method B for the preparation of **3w**.

Two of the remaining compounds listed in Table I, **3j** and **3j**, were obtained by treatment of **3a** with acetic anhydride and trifluoroacetic anhydride, respectively. The final compounds **3y** and **3z** were prepared directly from the  $\alpha$ -ethylthio adduct **3w**. Interestingly, treatment of **3w** with *m*-chloroperbenzoic acid in CH<sub>2</sub>Cl<sub>2</sub> led to the stereoselective production of the  $\alpha$ -sulfoxide **3y-1**. <sup>13</sup>C NMR analysis of the initial reaction mixture indicated the presence of only a single diastereomeric (enantiomeric pair) compound. The precise stereochemical identity of this adduct has not been established. Correspondingly, use of stoichiometric amounts of NaIO<sub>4</sub> at room temperature in an aqueous methanolic solution yielded a 2:1 diastereomeric mixture (<sup>13</sup>C NMR analysis) of **3y-1** and **3y-2** in which the major compound present corresponded to the product generated in the *m*-chloroperbenzoic acid reaction (**3y-1**). Attempts to completely separate these diastereomers by either TLC or recrystallization proved unsuccessful. Accordingly, a 2:3 mixture of **3y-1** and **3y-2** obtained after fractional recrystallization was analyzed for anticonvulsant activity and is identified as **3y-mix**. We have tentatively attributed the diastereoselectivity of the *m*-chloroperbenzoic acid mediated process to the preorganization of the oxidant with **3w** in CH<sub>2</sub>Cl<sub>2</sub>. Employment of excess NaIO<sub>4</sub> with **3w** at elevated temperatures (50–60 °C) gave the  $\alpha$ -sulfone **3z** in 32% yield.

Of note, all 17  $\alpha$ , $\alpha$ -diamino acid derivatives (**3a–q**), including the trimethylammonium adduct **3f** were well-

(9) Kober, R.; Steglich, W. *Liebigs Ann. Chem.* 1983, 599.

(10) Aldrich Chemical Co.

(11) Hogberg, T.; Strom, P.; Ebner, M.; Ramsby, S. *J. Org. Chem.* 1987, 52, 2022.

defined, stable compounds.<sup>12</sup> Only **3f**, **3i**, and **3k** melted with decomposition.

### Pharmacological Evaluation

The  $\alpha$ -heteroatom substituted amino acid derivatives **3** were tested for anticonvulsant activity by using the procedures described by Krall et al.<sup>13</sup> All compounds were administered intraperitoneally (ip) to mice. Table I lists the median effective dose (ED<sub>50</sub>) values required to prevent seizures in the MES test by racemic **3**. Included in this table are the median neurotoxic dose (TD<sub>50</sub>) values determined for select compounds using the horizontal screen test.<sup>14</sup>

Evaluation of the results listed in Table I revealed several important observations. First, the  $\alpha$ -amino (**3a**),  $\alpha$ -alkylamino (**3b-e**), and  $\alpha$ -trimethylammonium (**3f**) derivatives all displayed anticonvulsant activities comparable to that observed for the  $\alpha$ -methyl analogue **2a**.<sup>3,4</sup> Second, the  $\alpha$ -aryl amino derivatives **3g** and **3h** were devoid of activity at doses below 100 mg/kg. A comparable reduction in activity has been observed in proceeding from the  $\alpha$ -methyl derivative (**2a**) to the corresponding  $\alpha$ -benzyl adduct<sup>4</sup> and has been attributed (in part) to the stringent steric requirements that exist for maximal anticonvulsant activity in this class of compounds. Third, conversion of the  $\alpha$ -amino derivative **3a** to the corresponding  $\alpha$ -acylamino adducts **3i** and **3j** led to a decrease in activity of the test compound. Fourth, incorporation of an  $\alpha$ -*N*-alkoxyamino moiety (i.e., **3l**, **3n**, **3o**) within the backbone of the compound led to a pronounced improvement of the potency of the compound in the MES test compared to either **2a** or **3a**. A corresponding enhancement in activity was not observed for the two *N*-hydroxyamino adducts **3k** and **3m**. The anticonvulsant activities of racemic **3l** (ED<sub>50</sub> = 6.2 mg/kg) and **3n** (ED<sub>50</sub> = 6.7 mg/kg) were comparable to that of the (*R,S*)-2-furanyl derivative **2d**<sup>6</sup> (ED<sub>50</sub> = 10.3 mg/kg) and phenytoin<sup>7</sup> (ED<sub>50</sub> = 9.5 mg/kg). Importantly, in the most potent analogues (**2d**, **3l**, and **3n**), a functionalized oxygen atom existed two atoms removed from the  $\alpha$ -carbon atom. This pattern suggests that a substituted  $\beta$ -heteroatom may be necessary for maximal activity. Fifth, the  $\alpha$ -hydrazine derivatives **3p** and **3q** did not display significant anticonvulsant activity. Once again this property has been attributed (in part) to the steric size of these substituents. Sixth, the  $\alpha$ -hydroxy (**3r**) and the two  $\alpha$ -alkoxy adducts (**3s**, **3t**) displayed activity comparable to that reported for **2a**. The potency of the  $\alpha$ -oxygen series was somewhat diminished from that observed for the corresponding  $\alpha$ -amino derivatives (**3a-c**). In agreement with previous findings<sup>4</sup> the  $\alpha$ -phenoxy adduct **3u** displayed no activity at doses of 100 mg/kg or less. Seventh, within the  $\alpha$ -sulfur series, only the  $\alpha$ -ethylthio adduct **3w** exhibited anticonvulsant activity at doses less than 100 mg/kg. Eighth, no enhancement of activity was noted for the three sulfur-oxygenated derivatives **3y-1**, **3y-mix**, and **3z** versus **3w**. This observation is consistent with the results obtained for the two *N*-hydroxyamino adducts **3k** and **3m** versus **3a**.

(12) For recent reports on the preparation of  $\alpha,\alpha$ -diamino acid derivatives and related compounds, see: (a) Katritzky, A. R.; Urogi, L.; Mayence, A. *J. Chem. Soc., Chem. Commun.* 1989, 337. (b) Katritzky, A. R.; Urogi, L.; Mayence, A. *J. Org. Chem.* 1990, 55, 2206. (c) Bock, M. G.; DiPardo, R. M.; Freidinger, R. M. *Ibid.* 1986, 51, 3718. (d) Fischer, B.; Hassner, A. *Ibid.* 1990, 55, 5225 and references therein.

(13) Krall, R. L.; Penry, J. K.; White, B. G.; Kupferberg, H. J.; Swinyard, E. A. *Epilepsia* 1978, 19, 409.

(14) Coughenour, L. L.; McLean, R. R.; Parker, R. B. *Pharmacol.*

### Conclusions

Straightforward procedures have been employed for the preparation of  $\alpha$ -heteroatom-substituted amino acid derivatives. Despite the fact that these compounds have geminal heteroatoms  $\alpha$  to the carbonyl, they are chemically well-defined and are expected to serve as useful substrates in future chemical and pharmacological studies. The pharmacological data obtained in this investigation provided additional information concerning the structure-activity profile of functionalized amino acid anticonvulsants. The biological activities for **3** reinforced our notions that stringent steric and electronic requirements exist for maximal anticonvulsant activity in this class of compounds. The potencies of **3l** and **3n** in the MES test were comparable to those of phenytoin and **2d**. Additional studies in progress are aimed at investigating the generality of this class of compounds, as well as their mode of action.

### Experimental Section

**Chemistry. General Methods.** Melting points were determined with a Thomas-Hoover melting point apparatus and are uncorrected. Infrared spectra (IR) were run on Perkin-Elmer 1330 and 283 spectrometers and were calibrated against the 1601-cm<sup>-1</sup> band of polystyrene. Absorption values are expressed in wavenumbers (cm<sup>-1</sup>). Proton (<sup>1</sup>H NMR) and carbon (<sup>13</sup>C NMR) nuclear magnetic resonance spectra were taken on Nicolet NT-300 and General Electric QE-300 NMR instruments. Chemical shifts ( $\delta$ ) are in parts per million (ppm) relative to Me<sub>4</sub>Si, and coupling constants (*J* values) are in hertz. Low-resolution mass spectra (MS) were recorded at an ionizing voltage of 70 eV with a Varian MAT CH-5 spectrometer at the Lilly Research Laboratories. Microanalyses were provided by the Physical Chemistry Department of the Lilly Research Laboratories. Benzyl carbazate was obtained from Lancaster Synthesis Ltd., Windham, NH. Thin-layer chromatography were run on precoated silica gel GHLF microscope slides (2.5 × 10 cm; Analtech No. 21521).

**Preparation of  $\alpha$ -Heteroatom-Substituted Amino Acids (3). Method A. Synthesis of Ethyl 2-Acetamido-2-substituted-acetates. General Procedure.** A cooled (-78 °C) solution of **5**<sup>9</sup> (1 equiv) in THF (1 mmol/10 mL) was added slowly to a THF (1 mmol/4 mL) solution of the nitrogen nucleophile (5–10 equiv) at -78 °C. The reaction was stirred at this temperature (0.5 h) and then at room temperature (1 h). The insoluble materials were filtered and washed with THF. The filtrate was concentrated in vacuo, and the residue was purified by flash chromatography on SiO<sub>2</sub> gel (using the indicated solvent as the eluent) to give the desired product.

By use of this procedure, the following compounds were prepared.

**Synthesis of Ethyl 2-Acetamido-2-aminoacetate (6a).** Compound **5** (2.00 g, 8.93 mmol) and liquid NH<sub>3</sub> (5–6 equiv) yielded a light brown residue, which on purification by flash column chromatography on SiO<sub>2</sub> gel (5% MeOH/CHCl<sub>3</sub>) gave 1.00 g (70%) of **6a** as a yellow oil; *R*<sub>f</sub> 0.21 (5% MeOH/CHCl<sub>3</sub>); <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  1.31 (t, *J* = 7.1 Hz, 3 H), 2.03 (s, 3 H), 2.61 (br s, 2 H), 4.24 (q, *J* = 7.1 Hz, 2 H), 5.21 (d, *J* = 7.1 Hz, 1 H), 7.50 (d, *J* = 7.1 Hz, 1 H); <sup>13</sup>C NMR (CDCl<sub>3</sub>) 13.72, 22.68, 59.70, 61.73, 170.40, 170.68 ppm.

**Synthesis of Ethyl 2-Acetamido-2-(methylamino)acetate (6b).** Use of **5** (2.00 g, 8.93 mmol) and MeNH<sub>2</sub> (2.50 g, 80.6 mmol) gave an oily residue (1.50 g). The residue was purified by flash column chromatography on SiO<sub>2</sub> gel (3% MeOH/CHCl<sub>3</sub>) to yield 1.00 g (65%) of **6b** as an oil; *R*<sub>f</sub> 0.30 (3% MeOH/CHCl<sub>3</sub>); <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  1.32 (t, *J* = 7.1 Hz, 3 H), 2.07 (s, 3 H), 2.36 (s, 3 H), 4.26 (q, *J* = 7.1 Hz, 2 H), 5.20 (d, *J* = 7.4 Hz, 1 H), 6.60 (br s, 1 H) (the remaining amino proton was not detected); <sup>13</sup>C NMR (CDCl<sub>3</sub>) 14.02, 23.06, 30.84, 62.04, 65.72, 170.09, 170.40 ppm.

**Synthesis of Ethyl 2-Acetamido-2-(ethylamino)acetate (6c).** Employing **5** (2.10 g, 9.38 mmol) and EtNH<sub>2</sub> (1.40 g, 31.04 mmol) gave a brown residue. The residue was purified by flash column chromatography on SiO<sub>2</sub> gel (3% MeOH/CHCl<sub>3</sub>) to yield 0.90 g (51%) of **6c** as a light yellow oil; *R*<sub>f</sub> 0.36 (4% MeOH/CHCl<sub>3</sub>); <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  0.93 (t, *J* = 6.7 Hz, 3 H), 1.12 (t, *J*

$J = 6.8$  Hz, 2 H), 5.05 (d,  $J = 7.1$  Hz, 1 H), 7.09 (d,  $J = 7.1$  Hz, 1 H) (the remaining amino proton was not detected);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ ) 13.64, 14.55, 22.53, 39.06, 61.38, 64.14, 170.09, 170.20 ppm.

**Synthesis of Ethyl 2-Acetamido-2-(dimethylamino)acetate (6d).** Compound 5 (2.00 g, 8.93 mmol) and  $\text{Me}_2\text{NH}$  (5–6 equiv) gave 6d (1.50 g, 89%) as a yellow oil:  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  1.25 (t,  $J = 7.1$  Hz, 3 H), 2.02 (s, 3 H), 2.23 (s, 6 H), 4.10–4.25 (m, 2 H), 5.24 (d,  $J = 8.3$  Hz, 1 H), 6.59 (d,  $J = 8.3$  Hz, 1 H);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ ) 14.05, 23.00, 40.28 (2 C), 61.84, 69.24, 169.38, 170.57 ppm.

**Synthesis of Ethyl 2-Acetamido-2-(4-morpholino)acetate (6e).** Use of morpholine (1.71 g, 19.64 mmol) and 5 (2.00 g, 8.93 mmol) gave an oily residue, which was purified by flash column chromatography on  $\text{SiO}_2$  gel (2% MeOH/ $\text{CHCl}_3$ ) to give 1.90 g (93%) of 6e as a thick oil:  $R_f$  0.29 (3% MeOH/ $\text{CHCl}_3$ );  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  1.32 (t,  $J = 6.8$  Hz, 3 H), 2.07 (s, 3 H), 2.43–2.72 (m, 4 H), 3.58–3.78 (m, 4 H), 4.26 (q,  $J = 6.8$  Hz, 2 H), 5.27 (d,  $J = 7.9$  Hz, 1 H), 6.39 (d,  $J = 7.9$  Hz, 1 H);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ ) 14.21, 23.25, 48.47 (2 C), 62.06, 66.71 (2 C), 69.22, 169.00, 170.46 ppm.

**Synthesis of Ethyl 2-Acetamido-2-(*N*-anilino)acetate (6g).** Use of aniline (1.83 g, 19.6 mmol) and 5 (2.00 g, 8.93 mmol) provided a brown residue, which was purified by flash column chromatography on  $\text{SiO}_2$  gel ( $\text{CHCl}_3$ –2% MeOH/ $\text{CHCl}_3$  gradient) to yield 1.80 g (85%) of 6g: mp 87–89 °C (recrystallized from ethyl acetate/petroleum ether);  $R_f$  0.52 (4% MeOH/ $\text{CHCl}_3$ ); IR (KBr) 3340, 1720, 1635, 1590, 1490, 730, 710  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  1.29 (t,  $J = 7.1$  Hz, 3 H), 1.84 (s, 3 H), 4.27 (q,  $J = 7.1$  Hz, 2 H), 5.89 (d,  $J = 8.2$  Hz, 1 H), 6.43 (d,  $J = 8.2$  Hz, 1 H), 6.68–6.71 (m, 2 H), 6.80–6.83 (m, 1 H), 7.17–7.22 (m, 2 H) (the remaining amino proton was not detected);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ ) 13.96, 22.98, 60.19, 62.41, 113.87 (2 C), 119.29, 129.37 (2 C), 144.09, 169.77, 170.14 ppm; mass spectrum (FD) 237 ( $\text{M}^+ + 1$ ). Anal. ( $\text{C}_{12}\text{H}_{16}\text{N}_2\text{O}_3$ ) C, H, N.

**Synthesis of Ethyl 2-Acetamido-2-(3-pyrazolylamino)acetate (6h).** Use of 5 (2.00 g, 8.93 mmol) and 3-aminopyrazole (1.85 g, 22.32 mmol) and purification of the reaction product by chromatography on  $\text{SiO}_2$  gel (2% MeOH/ $\text{CHCl}_3$ ) gave 1.80 g (89%) of 6h as a yellow oil:  $R_f$  0.35 (8% MeOH/ $\text{CHCl}_3$ );  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  1.21 (t,  $J = 7.1$  Hz, 3 H), 1.89 (s, 3 H), 4.20 (q,  $J = 7.1$  Hz, 2 H), 5.64 (d,  $J = 1.8$  Hz, 1 H), 5.71 (br s, 1 H), 5.73 (d,  $J = 7.1$  Hz, 1 H), 7.29 (d,  $J = 1.8$  Hz, 1 H), 7.98 (d,  $J = 7.1$  Hz, 1 H) (the remaining amino proton was not detected);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ ) 13.73, 22.49, 61.41, 62.02, 91.79, 130.53, 153.02, 169.96, 170.93 ppm.

**Synthesis of Ethyl 2-Acetamido-2-(hydroxyamino)acetate (6k).** Use of 5 (2.10 g, 9.38 mmol) and anhydrous  $\text{NH}_2\text{OH}^{15}$  (0.93 g, 28.00 mmol) gave an oily residue. The residue was purified by flash column chromatography on  $\text{SiO}_2$  gel (5% MeOH/ $\text{CHCl}_3$ ) to give 1.00 g (61%) of 6k. The product was recrystallized from EtOH to give a white flaky solid: mp 119–121 °C;  $R_f$  0.24 (5% MeOH/ $\text{CHCl}_3$ ); IR (KBr) 3300, 1750, 1660, 1540, 1390, 610  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR ( $\text{DMSO}-d_6$ )  $\delta$  1.19 (t,  $J = 6.9$  Hz, 3 H), 1.87 (s, 3 H), 4.10 (q,  $J = 6.9$  Hz, 2 H), 5.09 (dd,  $J = 4.0, 8.0$  Hz, 1 H), 6.06 (br s, 1 H), 7.63 (s, 1 H), 8.50 (d,  $J = 8.0$  Hz, 1 H);  $^{13}\text{C}$  NMR ( $\text{DMSO}-d_6$ ) 14.05, 22.46, 60.82, 67.37, 169.19, 169.48 ppm; mass spectrum (FD) 177 ( $\text{M}^+ + 1$ ). Anal. ( $\text{C}_8\text{H}_{12}\text{N}_2\text{O}_4$ ) C, H, N.

**Synthesis of Ethyl 2-Acetamido-2-(methylhydroxyamino)acetate (6m).**  $\text{MeNHOH}$  (17.39 mmol) (prepared from  $\text{MeNH}_2\cdot\text{HCl}$  (2.00 g, 23.95 mmol) and  $\text{NaOMe}$  (0.94 g, 17.39 mmol)) and 5 (1.00 g, 4.46 mmol) gave an oily residue. The residue was triturated with EtOAc (5 mL) and the solid (0.70 g, 82%) that remained was filtered and recrystallized from EtOH to give 6m as a white solid: mp 148–150 °C;  $R_f$  0.34 (5% MeOH/ $\text{CHCl}_3$ ); IR (KBr) 3320, 3200 (br), 1760, 1660, 1530, 1470, 720, 640  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR ( $\text{DMSO}-d_6$ )  $\delta$  1.17 (t,  $J = 7.0$  Hz, 3 H), 1.89 (s, 3 H), 2.37 (s, 3 H), 4.00–4.20 (m, 2 H), 5.04 (d,  $J = 9.2$  Hz, 1 H), 8.17 (s, 1 H), 8.43 (d,  $J = 9.2$  Hz, 1 H);  $^{13}\text{C}$  NMR ( $\text{DMSO}-d_6$ ) 14.04, 22.28, 43.78, 60.79, 71.46, 168.29, 170.23 ppm; mass spectrum (FD) 192 ( $\text{M}^+ + 1$ ). Anal. ( $\text{C}_7\text{H}_{14}\text{N}_2\text{O}_4\cdot 0.25\text{H}_2\text{O}$ ) C, H, N.

**Synthesis of Ethyl 2-Acetamido-2-(methoxymethylamino)acetate (6n).**  $\text{MeNHOMe}$  (17.40 mmol) (prepared from  $\text{MeNHOMe}\cdot\text{HCl}$  (2.18 g, 22.32 mmol) and  $\text{NaOMe}$  (0.94 g, 17.40 mmol)) and 5 (1.00 g, 4.46 mmol) gave a residue, which was purified by flash column chromatography on  $\text{SiO}_2$  gel (1%

MeOH/ $\text{CHCl}_3$ ) to give 0.60 g (66%) of 6n as an oil:  $R_f$  0.53 (2% MeOH/ $\text{CHCl}_3$ );  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  1.35 (t,  $J = 7.0$  Hz, 3 H), 2.12 (s, 3 H), 2.62 (s, 3 H), 3.46 (s, 3 H), 4.30 (q,  $J = 7.0$  Hz, 2 H), 5.36 (d,  $J = 8.9$  Hz, 1 H), 6.66 (d,  $J = 8.9$  Hz, 1 H);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ ) 14.06, 22.89, 40.30, 60.01, 61.89, 70.16, 168.14, 170.53 ppm.

**Synthesis of 2-Acetamido-*N*-benzyl-2-substituted-acetamides (3). General Procedure.** A mixture of 6 (1 equiv), benzylamine (1.2 equiv), and NaCN (0.1 equiv) in MeOH (1 mmol/25 mL) was stirred at 45–50 °C (18 h). The solvent was removed in vacuo, and the residue was purified with either trituration with EtOAc or flash column chromatography on  $\text{SiO}_2$  gel (using the indicated solvent as the eluent).

By use of this procedure, the following compounds were prepared.

**Synthesis of 2-Acetamido-*N*-benzyl-2-aminoacetamide (3a).** Compound 6a (1.00 g, 6.25 mmol), benzylamine (0.80 g, 7.5 mmol), and NaCN (0.03 g, 0.61 mmol) gave a residue that solidified on standing (18 h). The reaction mixture was triturated with EtOAc (20 mL). The white solid (1.00 g, 72%) that remained was filtered and then further purified by recrystallization from EtOAc: mp 131–133 °C dec;  $R_f$  0.21 (5% MeOH/ $\text{CHCl}_3$ ); IR (KBr) 3300, 1650 (br), 1530 (br), 1450, 740  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR ( $\text{DMSO}-d_6$ )  $\delta$  1.83 (s, 3 H), 2.35 (br s, 2 H), 4.28 (d,  $J = 4.4$  Hz, 2 H), 4.91 (d,  $J = 7.0$  Hz, 1 H), 7.20–7.32 (m, 5 H), 8.31 (br s, 1 H), 8.51 (br s, 1 H);  $^{13}\text{C}$  NMR ( $\text{DMSO}-d_6$ ) 22.66, 42.05, 60.29, 126.67, 127.10 (2 C), 128.18 (2 C), 139.23, 169.24, 170.67 ppm; mass spectrum,  $m/e$  (relative intensity) 222 ( $\text{M}^+ + 1$ , 100), 221 ( $\text{M}^+$ , 29), 133 (8). Anal. ( $\text{C}_{11}\text{H}_{15}\text{N}_3\text{O}_2$ ) C, H, N.

**Synthesis of 2-Acetamido-*N*-benzyl-2-(methylamino)acetamide (3b).** Compound 6b (1.50 g, 8.63 mmol), benzylamine (1.11 g, 10.35 mmol), and NaCN (0.04 g, 0.82 mmol) gave a brown residue that was purified by flash column chromatography on  $\text{SiO}_2$  gel (2% MeOH/ $\text{CHCl}_3$ ) to yield 1.00 g (49%) of 3b: mp 115–117 °C (recrystallized from ethyl acetate/petroleum ether);  $R_f$  0.33 (3% MeOH/ $\text{CHCl}_3$ ); IR (KBr) 3240, 1610 (br), 1500 (br), 1430, 725, 670  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR ( $\text{DMSO}-d_6$ )  $\delta$  1.87 (s, 3 H), 2.18 (s, 3 H), 4.20–4.29 (m, 2 H), 4.87 (d,  $J = 7.9$  Hz, 1 H), 7.24–7.35 (m, 5 H), 8.14 (d,  $J = 7.9$  Hz, 1 H), 8.55 (br s, 1 H) (the remaining amino proton was not detected);  $^{13}\text{C}$  NMR ( $\text{DMSO}-d_6$ ) 22.52, 31.37, 42.04, 65.99, 126.68, 127.12 (2 C), 128.18 (2 C), 139.28, 169.51, 169.83 ppm. Anal. ( $\text{C}_{12}\text{H}_{17}\text{N}_3\text{O}_2$ ) C, H, N.

**Synthesis of 2-Acetamido-*N*-benzyl-2-(ethylamino)acetamide (3c).** Use of 6c (0.90 g, 4.79 mmol), benzylamine (0.62 g, 5.75 mmol), and NaCN (0.03 g, 0.51 mmol) gave an oily residue that was purified by flash column chromatography on  $\text{SiO}_2$  gel (3% MeOH/ $\text{CHCl}_3$ ) to give 0.35 g (29%) of 3c as a white solid: mp 123–125 °C (recrystallized from ethyl acetate/hexane);  $R_f$  0.34 (4% MeOH/ $\text{CHCl}_3$ ); IR (KBr) 3250, 1620 (br), 1510 (br), 1450 (br), 740, 680  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR ( $\text{DMSO}-d_6$ )  $\delta$  0.93 (t,  $J = 6.8$  Hz, 3 H), 1.81 (s, 3 H), 2.08 (br s, 1 H), 2.40–2.48 (m, 2 H), 4.22 (d,  $J = 5.5$  Hz, 2 H), 4.90 (d,  $J = 7.8$  Hz, 1 H), 7.20–7.27 (m, 5 H), 8.08 (d,  $J = 7.8$  Hz, 1 H), 8.48 (t,  $J = 5.5$  Hz, 1 H);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ ) 15.14, 22.97, 37.65, 43.53, 65.68, 127.44 (2 C), 127.50, 128.64 (2 C), 137.73, 169.75, 171.20 ppm. Anal. ( $\text{C}_{13}\text{H}_{19}\text{N}_3\text{O}_2$ ) C, H, N.

**Synthesis of 2-Acetamido-*N*-benzyl-2-(4-morpholino)acetamide (3e).** Use of 6e (0.59 g, 2.56 mmol), benzylamine (0.28 g, 2.82 mmol), and NaCN (0.01 g, 0.26 mmol) gave a thick oily residue. The residue was triturated with EtOAc (5 mL), and the white solid (0.35 g) that remained was collected by filtration to give 3e. The filtrate was concentrated, and the residue was purified by flash column chromatography on  $\text{SiO}_2$  gel (2% MeOH/ $\text{CHCl}_3$ ). The initial fractions furnished a trace amount (0.09 g) of 2-acetamido-*N*-benzyl-2-(benzylamino)acetamide. Continued elution gave additional amounts (0.20 g) of 3e.

**2-Acetamido-*N*-benzyl-2-(benzylamino)acetamide:** yield 0.09 g (11%); mp 135–138 °C;  $R_f$  0.52 (4% MeOH/ $\text{CHCl}_3$ ); IR (KBr) 3250 (br), 1630 (br), 1500 (br), 1425, 750, 700  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR ( $\text{DMSO}-d_6$ )  $\delta$  1.83 (s, 3 H), 3.52 (br s, 1 H), 3.56 (d,  $J = 13.6$  Hz, 1 H), 3.66 (d,  $J = 13.6$  Hz, 1 H), 4.23 (d,  $J = 5.4$  Hz, 2 H), 4.89 (d,  $J = 8.0$  Hz, 1 H), 7.05–7.38 (m, 10 H), 8.20 (d,  $J = 8.0$  Hz, 1 H), 8.51 (t,  $J = 5.4$  Hz, 1 H);  $^{13}\text{C}$  NMR ( $\text{DMSO}-d_6$ ) 22.63, 42.11, 48.57, 64.41, 126.70, 127.13 (2 C), 128.00 (2 C), 128.13 (2 C), 128.22 (2 C), 128.30, 139.29, 140.12, 169.61, 169.90 ppm; mass spectrum,  $m/e$  (relative intensity) 312 ( $\text{M}^+ + 1$ , 12), 311 ( $\text{M}^+$ , 7), 178 (11), 157 (100). Anal. ( $\text{C}_{20}\text{H}_{25}\text{N}_3\text{O}_2$ ) C, H, N.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.